Genflow Biosciences PLC (LSE: GENF), a leading company in the field of longevity, has revealed plans to reorganize its primary board of directors and scientific advisory board (SAB) in order to harmonize with its current goals and priorities in the United States, including an upcoming listing on the OTC market.
US-based non-executive director Tamara Joseph has been appointed chairperson of the board, in recognition of her considerable experience in financing and understanding of the US public markets. Joseph has facilitated Nasdaq financings surpassing US$800mln and has counselled the boards of five US publicly listed biotech firms.
Moreover, Vera Gorbunova, a biology professor at the University of Rochester, New York, and joint director of the Rochester Ageing Research Center, has been elevated to the position of chairperson of the SAB. Gorbunova’s research revolves around longevity mechanisms and genome stability. Her insights into longevity research will play a crucial role in steering the company’s scientific investigations, according to investors.
The company also declared the inclusion of Professor Sven Francque to the SAB. Known for his expertise in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, his comprehensive knowledge will aid Genflow in pinpointing new targets and possible treatments for the disease, the company explained.
In particular, Francque’s proficiency in clinical research and clinical trial design will prove to be indispensable for the progress of Genflow’s clinical trial initiatives.
Genflow director Yassine Bendiabdallah stated: “Our commitment to adjust and evolve in the constantly changing longevity landscape remains unswerving. Our collective and individual adaptability provides us with a major edge over larger competitors, enabling us to maintain a leading position in this dynamic industry.”
Comment: The market clearly liked the recent announcement from GENF revealing that it has a two-year cash runway, something which has rather stopped the mudslinging from the bears in its tracks. Today’s RNS should allow the shares to build on last month’s recovery.
